Literature DB >> 25724678

RIP1 Kinase Is an Oncogenic Driver in Melanoma.

Xiao Ying Liu1, Fritz Lai2, Xu Guang Yan2, Chen Chen Jiang2, Su Tang Guo3, Chun Yan Wang3, Amanda Croft2, Hsin-Yi Tseng2, James S Wilmott4, Richard A Scolyer4, Lei Jin5, Xu Dong Zhang5.   

Abstract

Although many studies have uncovered an important role for the receptor-binding protein kinase RIP1 in controlling cell death signaling, its possible contributions to cancer pathogenesis have been little explored. Here, we report that RIP1 functions as an oncogenic driver in human melanoma. Although RIP1 was commonly upregulated in melanoma, RIP1 silencing inhibited melanoma cell proliferation in vitro and retarded the growth of melanoma xenografts in vivo. Conversely, while inducing apoptosis in a small proportion of melanoma cells, RIP1 overexpression enhanced proliferation in the remaining cells. Mechanistic investigations revealed that the proliferative effects of RIP1 overexpression were mediated by NF-κB activation. Strikingly, ectopic expression of RIP1 enhanced the proliferation of primary melanocytes, triggering their anchorage-independent cell growth in an NF-κB-dependent manner. We identified DNA copy-number gain and constitutive ubiquitination by a TNFα autocrine loop mechanism as two mechanisms of RIP1 upregulation in human melanomas. Collectively, our findings define RIP1 as an oncogenic driver in melanoma, with potential implications for targeting its NF-κB-dependent activation mechanism as a novel approach to treat this disease. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25724678     DOI: 10.1158/0008-5472.CAN-14-2199

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  ACTN4 regulates the stability of RIPK1 in melanoma.

Authors:  Yuan Yuan Zhang; Hessam Tabataba; Xiao Ying Liu; Jia Yu Wang; Xu Guang Yan; Margaret Farrelly; Chen Chen Jiang; Su Tang Guo; Tao Liu; Hung-Ying Kao; Rick F Thorne; Xu Dong Zhang; Lei Jin
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

2.  RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression.

Authors:  Waise Quarni; Panida Lungchukiet; Anfernee Tse; Pei Wang; Yuefeng Sun; Ravi Kasiappan; Jheng-Yu Wu; Xiaohong Zhang; Wenlong Bai
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-01       Impact factor: 4.292

3.  The double life of RIPK1.

Authors:  Lei Jin; Jiezhong Chen; Xiao Ying Liu; Chen Chen Jiang; Xu Dong Zhang
Journal:  Mol Cell Oncol       Date:  2015-05-26

Review 4.  Molecular Pathways: The Necrosome-A Target for Cancer Therapy.

Authors:  Lena Seifert; George Miller
Journal:  Clin Cancer Res       Date:  2016-12-08       Impact factor: 12.531

Review 5.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

6.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.

Authors:  Radoslav Janostiak; Navin Rauniyar; TuKiet T Lam; Jianhong Ou; Lihua J Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

7.  RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC.

Authors:  Cong Wang; Bowen Yao; Meng Xu; Xin Zheng
Journal:  Tumour Biol       Date:  2016-10-04

8.  Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors.

Authors:  Fatemeh Karami-Tehrani; Amin Rahimi Malek; Zahra Shahsavari; Morteza Atri
Journal:  Tumour Biol       Date:  2016-01-09

9.  Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases.

Authors:  Yue Li; Marita Führer; Ehsan Bahrami; Piotr Socha; Maja Klaudel-Dreszler; Amira Bouzidi; Yanshan Liu; Anna S Lehle; Thomas Magg; Sebastian Hollizeck; Meino Rohlfs; Raffaele Conca; Michael Field; Neil Warner; Slae Mordechai; Eyal Shteyer; Dan Turner; Rachida Boukari; Reda Belbouab; Christoph Walz; Moritz M Gaidt; Veit Hornung; Bernd Baumann; Ulrich Pannicke; Eman Al Idrissi; Hamza Ali Alghamdi; Fernando E Sepulveda; Marine Gil; Geneviève de Saint Basile; Manfred Hönig; Sibylle Koletzko; Aleixo M Muise; Scott B Snapper; Klaus Schwarz; Christoph Klein; Daniel Kotlarz
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-27       Impact factor: 11.205

10.  NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.

Authors:  Hanan S Elsarraj; Kelli E Valdez; Yan Hong; Sandra L Grimm; Lawrence R Ricci; Fang Fan; Ossama Tawfik; Lisa May; Therese Cusick; Marc Inciardi; Mark Redick; Jason Gatewood; Onalisa Winblad; Susan Hilsenbeck; Dean P Edwards; Christy R Hagan; Andrew K Godwin; Carol Fabian; Fariba Behbod
Journal:  Cancer Res       Date:  2017-05-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.